SCHEMBL6036366

SCHEMBL6036366

CCOC(=O)CCc1c[nH]nc1OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.49
CYP4A11 Q02928 3/20 0.49
ALOX5 P09917 1/20 0.44
PPARG P37231 1/20 0.44
PPARD Q03181 1/20 0.44
PPARA Q07869 1/20 0.44
ABCB1 P08183 1/20 0.44
MAPT P10636 2/20 0.43
TDP1 Q9NUW8 1/20 0.42
NR1H4 Q96RI1 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPK1 P28482 1/20 0.42
LMNA P02545 3/20 0.41
TP53 P04637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5111772 0.84 CYP4F2 (0.48) CYP4F2CYP4A11MAPTCYP1A2CYP3A4
SCHEMBL3080180 0.78 L3MBTL1 (0.53) NR1H4NPSR1L3MBTL1KDM4E
SCHEMBL5371838 0.77 CYP4F2 (0.54) CYP4F2CYP4A11MAPTCYP1A2CYP3A4
SCHEMBL5403139 0.77 CYP4F2 (0.48) CYP4F2CYP4A11PPARGPPARDPPARA
SCHEMBL28454621 0.74 CYP4F2 (0.53) CYP4F2CYP4A11ABCB1MAPTTDP1
SCHEMBL10635313 0.74 CYP4F2 (0.53) CYP4F2CYP4A11PPARGPPARDPPARA
SCHEMBL6035792 0.74 CYP4F2 (0.50) CYP4F2CYP4A11ALOX5ABCB1MAPT
SCHEMBL3091164 0.74 FFAR1 (0.68) CYP4F2CYP4A11ALOX5TDP1NR1H4
SCHEMBL6472786 0.74 CYP4F2 (0.44) CYP4F2CYP4A11ALOX5MAPTNR1H4
Ethyl 3-Phenylpropanoate SCHEMBL304816 0.73 TDP1 (0.75) CYP4F2CYP4A11ALOX5ABCB1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 CYP4F2 90/4885CYP4A11 18/4885ALOX5 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.